ifa Systems AG, the global leader for IT solutions in ophthalmology based in Cologne, Germany, announced the acquisition of inoveon Corporation, proven experts in detection, staging, and monitoring of diabetic retinopathy and macular edema. The acquisition took place on December 29, 2010.
ifa Systems, founded over 20 years ago, is a leading provider of software applications in international ophthalmology. They are most noted for their pioneering work in the sophisticated Electronic Health Record (EHR) system for ophthalmology that has been adopted extensively in Europe, Latin America and has now been introduced into the North American and Asian markets.
inoveon Corp. is a premier medical services company, focused on managing diabetic eye disease, clinical research and development. Drs. Lloyd Hildebrand and Stephen Fransen, ophthalmic surgeons at the University of Oklahoma's Dean McGee Eye Institute, founded the company in 1997. Both ifa Systems and inoveon have previously collaborated in developing open clinical and health information technology standards, which greatly complement one another when used in the eye clinics and ophthalmic supply networks.
The merging of the companies means significant changes for both groups. For ifa, it will broaden their product line and distribution structure and will add to their rapid growth by furthering their international market share in 17 countries managing more than 70 million patients' data.
For inoveon, it means Oklahoma City will become a hub for international telemedicine activities, including service development and consulting activities. It will mean further extensions of the inoveon platform, as their services expand to include new services for ifa Systems' installed client base.
Customers and partners of inoveon will now see benefits from ifa Systems' market presence and the additional extensions to the inoveon platform. ifa Systems AG is listed in the Entry Standard of the Frankfurt Stock Exchange (symbol IS8).
Long-term low-dose antiviral treatment reduces eye disease risk from shingles